Making an imperfect marker better

European Urology

Volumn 59, Issue 2, 2011, Pages 194-196

  Freedland, Stephen J ^a   Andriole, Gerald L ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; BIOPSY; CANCER RISK; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 78650703445     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.11.022     Document Type: Editorial

References (8)

1. E.D. Crawford, and P.-A. Abrahamsson PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 54 2008 262 273
2. R.S. Punglia, A.V. D'Amico, W.J. Catalona, K.A. Roehl, and K.M. Kuntz Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen N Engl J Med 349 2003 335 342
3. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
4. I.M. Thompson, C. Chi, and D.P. Ankerst Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 98 2006 1128 1133
5. Andriole GL, Bostwick DG, Brawley OW, et al. The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. In press. doi:10.1016/j.juro.2010.09.011.
6. G.L. Andriole, H.A. Guess, and J.I. Epstein Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS study group. Proscar Long-Term Efficacy and Safety Study Urology 52 1998 195 201 discussion 201-2
7. P.J. van Leeuwen, K. Kölble, and H. Huland Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies Eur Urol 59 2011 183 190
8. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter N Engl J Med 350 2004 2239 2246